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AIDS   acquired immunodeficiency syndrome  
ALT   alanine aminotransferase  
FeLV   feline leukemia virus  
FIV   feline immunodeficiency virus  
HIV   human immunodeficiency virus  
IFA  indirect immunofluorescence assay 
IQR  interquartile range 
MCHC  mean corpuscular hemoglobin concentration 
MCV  mean corpuscular volume 
OR   odds ratio 
PCR   polymerase chain reaction 
95% CI   95% confidence interval 
 
 
 
Abstract  
 
Background: The clinical course and outcome of natural feline immunodeficiency virus (FIV) infection 
are variable and incompletely understood. Assigning clinical relevance to FIV infection in individual cats 
represents a considerable clinical challenge. 
Objective: To compare signalment, hematologic and biochemical data, major clinical problem and 
survival between client-owned, FIV-infected and uninfected domestic cats. 
Animals: Client-owned, domestic cats tested for FIV (n=520). 
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Methods:  Retrospective, case control study. Logistic regression analyses were conducted to identify risk 
factors for FIV infection and to compare hematologic and biochemical data between cases and controls, 
after adjusting for potential confounders. Survival times were compared using Kaplan-Meier curves. 
Results: The prevalence of FIV infection was 14.6%. Mixed breed, male sex and older age were risk 
factors for FIV infection. Hematologic abnormalities, biochemical abnormalities, or both were common 
in both FIV-infected and uninfected cats. Lymphoid malignancies were slightly more common in FIV-
infected than uninfected cats. Survival of FIV-infected cats was not significantly different from that of 
uninfected cats. 
Conclusions and clinical importance: Multiple hematologic and biochemical abnormalities are common 
in old, sick cats regardless of their FIV status. Their presence should not be assumed to indicate clinical 
progression of FIV infection. A negative effect of FIV on survival was not apparent in this study.  
 
Keywords: Clinicopathological findings; Feline immunodeficiency virus; survival. 
 
 
 
Feline immunodeficiency virus (FIV) is a common pathogen of domestic cats worldwide.1 The number of 
FIV-infected pet cats in the USA alone is estimated to exceed 2.5 million.2,3 Most natural infections likely 
result from inter-cat aggression whereas transmission from queens to kittens and between cats within 
stable, closed households seems to be rare.4,5 Risk factors for infection, including male sex, intact status, 
outdoor access, increasing age and concurrent health problems are well documented.2,4,6 
 
FIV is closely related to human immunodeficiency virus (HIV) with regard to its morphology, in vitro 
characteristics and elements of its pathogenesis.1 In cats experimentally infected with FIV, progressive 
aberrations in multiple parameters of immune function, such as lymphocyte subset counts and mitogen 
responsiveness, have been documented.7 Interestingly, these changes are rarely associated with clinical 
signs. This may be attributed to limited exposure to secondary and opportunistic pathogens in a minimal 
disease setting, genetic characteristics of the host or the dose and strain of the infecting inoculum.  
 
Disease in HIV-infected humans without access to anti-retroviral treatments is quite predictable, 
progressing through well-defined clinical stages: acute phase, asymptomatic carrier, persistent generalized 
lymphadenopathy, acquired immunodeficiency syndrome (AIDS)-related complex and AIDS. The median 
time to the onset of the terminal AIDS stage is 8 to 10 years.8 This stage is characterized by ‘AIDS-defining’ 
illnesses, many of which are rare except in the face of profound immunosuppression (e.g., Pneumocystis 
pneumonia). Disease staging includes consideration of the patient’s CD4+ lymphocyte count which, 
together with plasma viral load, provides a surrogate marker to predict clinical outcome.9 
 
The clinical course of FIV infection, on the other hand, is less well characterized or predictable. Attempts 
at clinical staging of FIV-infected cats have been attempted but not widely adopted.10 A wide range of 
clinical signs has been reported in cats naturally infected with FIV, including oral disease, persistent 
cytopenias, immune-mediated disease, unexplained wasting, atypical, refractory or recurrent infections, 
and neurologic signs.4,11 However, few of these signs have been demonstrated to be significantly 
different from those of control populations. With the exception of a subset of lymphomas, AIDS-defining 
illnesses are not recognized for FIV.12 Furthermore, some FIV-infected cats remain asymptomatic with a 
normal life expectancy.5 
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The challenge for the clinician faced with a sick, FIV-infected cat is determining whether the virus is 
contributing to the current clinical signs. Studies comparing clinicopathological findings and outcomes 
between cats infected with FIV and appropriate control groups can inform our understanding of the 
consequences of natural infection, but such studies are limited.13-18 The aims of this study were to 
compare the hematologic and biochemical changes, major clinical problem and survival between groups 
of client-owned, FIV-infected and uninfected cats. Prevalence and risk factors for FIV infection also were 
determined.  
 
Materials and methods 
 
Source of data 
The medical records of the Valentine Charlton Cat Centre, University of Sydney, were searched, using the 
terms FIV and feline immunodeficiency virus, for FIV testing results recorded between January 2005 and 
October 2009. The clinical indication for retrovirus testing had been determined by the attending clinician. 
 
FIV and feline leukemia virus (FeLV) testing  
Serology for FIV and feline leukemia virus (FeLV) was performed using commercial kits.a,b Polymerase 
chain reaction (PCR) testing for FIV was carried out at a commercial laboratory.c The sensitivity and 
specificity of this assay have been estimated to be 85-95% and 94-96%, respectively.19 The FeLV indirect 
immunofluorescence assay (IFA) was performed at a commercial laboratory.d 
 
Case and control definitions 
A cat was defined as ‘FIV-infected’ if it tested seropositive for FIV and had not been vaccinated,e as 
determined from the medical record or direct owner communication. A cat was considered to be ‘FIV-
uninfected’ if it tested seronegative or it tested seropositive and had been vaccinated but had returned 
a negative result on FIV PCR testing. FIV seropositive, vaccinated cats with unknown PCR status and 
seropositive cats with unknown vaccination and PCR status were excluded. A FeLV antigen test was 
considered to be positive if a positive result on in-house testing was confirmed by IFA, or the cat was in 
contact with an antigenemic cat.  
 
Data collection 
Information obtained from the medical record including breed, sex, neuter status, date of FIV testing, FeLV 
antigen status (where tested) and date of death were recorded for FIV-infected (n=76) and FIV-uninfected 
(n=444) populations. The first hematologic and biochemical data, performed by Veterinary Pathology 
Diagnostic Services, University of Sydney, subsequent to FIV testing were recorded for FIV-infected cats 
(n=75, data unavailable for 1 cat) and a subset of the control population (n=231) that was selected using 
random numbers.f The median time lag between testing and hematologic and biochemical data collection 
was 0 days for both FIV-infected and control groups (FIV infected; range, 0-4179 days; interquartile range 
[IQR], 179; uninfected; range, 0-232 days; IQR, 1). The major clinical problem in these cats was assigned to 
1 of 10 categories: cardiorespiratory, endocrine, gastrointestinal, genitourinary, healthy, immune-
mediated, infectious, neoplasia, neurologic or not determined. Within the neoplasia category, the 
prevalence of lymphoid versus other malignancies was determined.  
 
Data analysis 
Statistical software was used for all analyses.g All p values were 2-sided and considered significant at <0.05. 
For risk factor and survival analyses, data from 520 cats were used, 76 infected cats and 444 uninfected 
controls. For analysis of analytes, data from 306 cats were used, 75 infected cats and 231 uninfected 
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controls. Descriptive analyses were conducted to understand the distribution of variables and their 
preliminary association with FIV status.  
 
Three sets of logistic regression analyses then were performed. The first set of analyses was conducted to 
identify any association between ‘FIV status’ and the demographic factors ‘breed’, ‘sex’, ‘neuter status’ 
and ‘age at FIV testing’. Similar logistic regression analyses were conducted to evaluate the association 
between ‘FIV status’ and hematologic and biochemical variables. To further compare the hematologic and 
biochemical data between FIV-infected and control cats, each hematologic and biochemical value was 
classified as decreased, normal or increased for each cat and a third set of logistic regression analyses was 
conducted to compare analyte concentrations between FIV-infected and uninfected cats. Age and sex of 
cats were considered potential confounders and forced into the models for hematologic and biochemical 
variables, even if not significant. Univariable and multivariable model building was performed.20,h 
 
The major clinical problem was compared between FIV-infected cats and the control sample using the 2- 
tailed Fisher’s exact test. The only FeLV antigenemic cat had lymphoma and was excluded from analysis of 
major clinical problem. 
 
Two survival analyses using the Kaplan-Meier approach were conducted to compare survival between FIV-
infected and uninfected cats. The first analysis compared the age at the time of data collection (i.e. date of 
death or censoring - date of birth) whereas the second analysis compared survival time at the time of data 
collection (i.e. date of death or censoring - date of testing). All surviving cats were censored at the date of 
their last visit to the clinic or at the time of data collection (17th August, 2010), whichever was earlier. Log 
rank test was used for comparisons.  
 
Results 
 
FIV and FeLV testing 
Five hundred twenty-five cats were tested for FIV during the study period. Seventy-six FIV seropositive cats 
that had not been vaccinated against FIV were considered to be FIV-infected. Five cats that tested 
seropositive for FIV but with undetermined vaccination status, tested negative on PCR and were 
considered to be FIV-uninfected. The infection status of 5 FIV seropositive cats could not be determined 
and they were excluded. The 439 cats that were seronegative were considered to be FIV-uninfected. In 
total, 76 FIV-infected cats and 444 FIV-uninfected cats were available for study. The prevalence of FIV was 
14.6%. A single, FIV-uninfected cat was positive for FeLV antigen giving a prevalence of less than 0.2%.  
 
Analysis of risk factors of FIV infection 
The mean age at testing was 9.8 (+/- 4.3) years and 7.8 (+/- 5.2) years for FIV-infected and uninfected 
groups, respectively. Mixed breed, male and neutered cats made up 88.2%, 76.3% and 5.3% of the 
infected group in comparison to 66.2%, 51.1% and 6.8% respectively of the uninfected group. The final 
multivariable model had 3 significant variables, ‘age at FIV testing’, ‘sex’ and ‘breed’. The assumption of 
linearity for ‘age at FIV testing’ was invalid, therefore, it was split into 4 categories: age ≤ 5 years, >5 to 10 
years, >10 to 15 years and >15 years. Results for the final model demonstrated that the risk of being FIV-
infected was greater for cats over 5 years of age than for cats of 5 years of age or younger. Female cats 
(odds ratio [OR], 0.30; 95% CI, 0.17, 0.53) and purebred cats (OR, 0.28; 95% CI, 0.13, 0.56) were less likely 
to be FIV positive.   
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Analysis of hematologic and biochemical data 
Hematologic and biochemical results were analyzed for potential associations with FIV status. Of the 33 
analytes evaluated, 9 had p values <0.25 in univariable logistic regression analyses (Table 1). After 
adjusting for potential confounders, age and sex, only sodium was significant in the final logistic regression 
model. The assumption of linearity for sodium was not valid, therefore the cubic spline was fitted (not 
shown). The results indicated that the log odds of being FIV-infected is increased as the sodium 
concentration increased above 150 mmol/L.  
 
Comparison of hematologic and biochemical parameters for FIV-infected and FIV-uninfected cats with 
normal range for each analyte. 
Logistic regression analyses were conducted by categorizing all hematologic and biochemical parameters 
into 3 categories: decreased, normal and increased. Of the 33 analytes evaluated, 11 were significant at a 
liberal p-value of 0.25 (Table 2). PCV, chloride, MCH and MCHC were excluded from further analyses due 
to 0 or low frequencies for some cells.  Only plasma sodium concentration and monocyte count were 
significant in the final model after adjusting for age and sex (Table 3). Compared with controls, the cases 
had greater odds of hypernatremia and decreased odds of hyponatremia. FIV-infected cats were at 
increased risk of monocytopenia (Table 3). 
 
Hematologic and clinicopathological abnormalities that may be attributed to FIV infection, when it is 
present, are presented in Table 4. There was no significant difference in the frequency of these 
abnormalities between infected and control groups. Uninfected cats were as likely, or more likely, to be 
leukopenic, lymphopenic, hyperproteinemic, hyperglobulinemic and azotemic than FIV-infected cats.  
 
Table 1. Summary statistics of the association of hematologic and biochemical parameters with FIV 
status.  
 
Variable Status 
           
N Minimum Lower  Median Upper  Maximum   
    Quartile  Quartile  p-value
i
 
 
FIV-infected 50 0.16 0.28 0.33 0.37 0.44 
 PCV 
(L/L) FIV-uninfected 162 0.05 0.25 0.31 0.36 0.46 0.052 
     
 
   
 
FIV-infected 51 50.0 95.0 116.0 127.0 161.0 
 Hb 
(g/L) FIV-uninfected 167 6.6 89.0 107.0 124.0 160.0 0.057 
         
 
FIV-infected 50 37.1 43.3 46.05 49.7 60.2 
 MCV 
(fl) FIV-uninfected 153 33.1 41.4 44.4 46.7 84.8 0.074 
         
 
FIV-infected 50 13.5 14.7 15.8 17.2 19.5 
 MCH  
(pg) FIV-uninfected 160 1.6 14.05 15.2 16.3 24.2 0.006 
                                                        
i The p-values are for likelihood ratio chi-square test based on univariable logistic regression anlayses. 
Results are presented for only variables with p-value <0.25. 
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FIV-infected 50 312.0 335.0 343.0 353.0 400.0 
 MCHC 
(g/L) FIV-uninfected 166 24.0 331.0 341.5 355.0 438.0 0.21 
         
 
FIV-infected 38 13.3 26.8 29.7 33.4 39.3 
 Albumin 
(g/L) FIV-uninfected 131 7.43 29.3 32.5 34.7 43.0 0.022 
         
 
FIV-infected 36 1.8 2.8 3.4 4.5 137.0 
 Cholesterol 
(mmol/L) FIV-uninfected 129 1.6 2.9 3.5 4.7 137.0 0.097 
         
 
FIV-infected 34 11.0 126.0 221.5 330.0 1323.0 
 CK 
(U/L) FIV-uninfected 125 52.0 111.0 197.0 345.0 12726.0 
 
        
0.18 
 
FIV-infected 35 132.4 146.4 151.5 155.8 162.1 
 Sodium 
(mmol/L) FIV-uninfected 130 126.4 139.7 144.6 148.7 172.6 <0.001 
         
          
Variables also examined but not significant (p>0.25) were absolute erythrocyte reticulocyte, leukocyte, neutrophil  
(segmented and band), monocyte, eosinophil, basophil, lymphocyte and platelet counts, inorganic phosphate, 
glucose, creatinine, urea, total calcium, alanine aminotransferase, alkaline phosphatase, bilirubin, total protein, 
globulin, potassium, and chloride. 
 
 
Table 2. Contingency tables of categorized hematologic and biochemical variables with FIV status.  
 
Variables Categories 
FIV -infected 
(%) 
FIV -uninfected 
 (%)   Total p-value
ii
 
Sodium (mmol/L) 
    
<0.001 
 
Decreased (≤ 147) 10 (28.6%) 81 (62.1%) 91 
 
 
Normal (>147 to 156) 18 (51.4%) 44 (33.9%) 62 
 
 
Increased (>156) 7 (20%)  5(3.9 %) 12 
 Chloride (mmol/L) 
    
0.001 
 
Decreased (≤115) 7 (20%) 64 (50.8%) 71 
 
 
Normal (>115-130) 28 (80%) 62 (48.4%) 90 
 
 
Increased (>130)
1
 0 (0.0%) 2 (1.6) 0 
 MCH (pg) 
    
0.003 
 
Decreased (≤13)
2
 0 (0.0%) 16 (10.0%) 16 
 
 
Normal (>13-17)            36 (72.0%)    125 (78.1%) 161 
                                                         
ii The p-values are for likelihood ratio chi-square test based on univariable logistic regression anlayses. 
Results are presented for only variables with p-value <0.25. 
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Increased (>17) 14 (28.0%) 19 (11.9%) 33 
 Monocytes x10
9
/L 
    
0.03 
 
Decreased (≤0.08) 8 (15.4%) 8 (5%) 16 
 
 
Normal (>0.08-0.56) 33 (64.5%) 98 (61.3%) 131 
 
 
Increased (>0.56) 11 (21.1%) 54 (33.8%) 65 
 Bilirubin (µmol/L) 
    
0.11 
 
Decreased (≤2.5) 11 (57.9%) 37 (32.5%) 48 
 
 
Normal (>2.5-3.5) 4 (21.1%) 35 (30.7%) 39 
 
 
Increased (>3.5) 4 (21.1%) 42 (36.8%) 46 
 Creatinine (µmol/L) 
    
0.17 
 
Decreased (≤90) 4 (9.5%) 24 (16.9%) 28 
 
 
Normal (>90-180) 27 (64.3%) 97 (68.3%) 124 
 
 
Increased (>180) 11 (26.2%) 21 (14.8%) 32 
 Hb (g/L) 
    
0.11 
 
Decreased (≤80) 3 (5.9%) 27 (16.2%) 30 
 
 
Normal (>80-140) 45 (88.2%) 128 (76.7%) 173 
 
 
Increased (>140) 3 (5.9%) 12 (7.2%) 15 
 MCV (fl) 
    
0.14 
 
Decreased (≤40)) 6 (12%) 26 (17%) 32 
 
 
Normal (>40-45) 15 (30%) 63 (41.2%) 78 
 
 
Increased (>45) 29 (58%) 64 (41.8%) 93 
 Calcium (mmol/L) 
    
0.18 
 
Decreased (≤1.75) 3 (7.3%) 2 (1.4%) 5 
 
 
Normal (>1.75-2.6)    27 (65.9%) 101 (72.7%) 128 
 
 
Increased (>2.6) 11 (26.8%) 36 (25.9%) 47 
 PCV (L/L) 
    
0.15 
 
Decreased (≤0.30)  19 (38.0%) 80 (49.4%) 99 
 
 
Normal (>0.30-0.45) 31 (62.0%) 81 (50.0%) 112 
 
 
Increased (>0.45)
1
 0 (0.0%) 1 (0.6) 1 
 MCHC (g/L) 
    
0.18
2
 
 
Decreased (≤310) 
2
 0 (0.0%) 8 (4.8%) 8 
 
 
Normal (>310-350) 37 (74%) 104 (62.7%) 141 
 
 
Increased (>350) 13 (26%) 54 (32.5%) 67 
  
1 
These categories were excluded from logistic regression analyses due to very small frequencies. 
2
 The p-values are for Fisher’s exact test as logistic regression model could not converge due to some zero cell 
frequencies. 
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Table 3. The final logistic regression model to evaluate association of categorized hematologic and 
biochemical parameters with FIV status.  
Variables Categories b SE 
Adjusted  
odds ratios
iii
 
95%  
Confidence  
intervals p-value 
Intercept  -3.50 0.91    
Sodium      0.001 
 Normal (>147 to 156) 0.00  1.00   
 Decreased (≤ 147) -1.04 0.48 0.35 0.13, 0.89  
 Increased (>156) 1.89 0.83 6.63 1.41, 38.11  
Monocytes      0.035 
 Normal (>0.08 to 0.56) 0.00  1.00   
 Decreased (≤ 0.08) 1.96 0.81 7.13 1.50, 37.18  
 Increased (>0.56) -0.14 0.51 0.87 0.31, 2.34  
Gender      0.017 
 Female 0.00  1.00   
 Male 1.24 0.52 3.44 1.31, 10.10  
Age at diagnosis     0.053 
 ≤5 years 0.00  1.00   
 >5 to 10 years 1.60 0.86 4.95 1.08, 36.56  
 >10 years to 15 years 2.25 0.85 9.51 2.16, 70.34  
 >15 years 1.14 0.99 3.14 0.49, 27.14  
 
Table 4. Comparison of abnormalities commonly attributed to FIV infection in infected and uninfected 
cats.  
 
abnormality 
FIV-infected FIV-uninfected
iv
 
affected/total 
(%) 
affected/total 
(%) 
leukopenia 21/52 
(40.4) 
66/161 
(40.9) 
neutropenia 20/52 
(38.5) 
54/161 
(33.5) 
lymphopenia 27/53 
(50.9) 
80/162 
(49.4) 
hyperproteinemia 20/50 
(40) 
74/152 
(48.7) 
hyperglobulinemia 8/37 
(21.6) 
30/129 
(23.3) 
increased creatinine 4/42 
(9.5) 
24/142 
(16.9) 
increased urea 7/43 
(16.3) 
33/145 
(22.8) 
                                                        
iii Odds ratios are adjusted for other variables in the model and are interpreted in the same manner as 
descibed in Figure 1. For example, compared to FIV negative cats, FIV positive cats had 6.63 times odds of 
having increased sodium concentrations and 7.13 times odds of decreased monocyte counts. 
iv There was no significant difference in these variables between FIV-infected and uninfected populations 
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Table 5. The major clinical problem in FIV infected and uninfected cats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparison of major clinical problem between FIV-infected and uninfected cats 
 The major clinical problems identified in FIV-infected cats and the control sample are presented in Table 
5. Almost 95% of all cats tested for FIV presented with clinical problems. In both groups, the most common 
clinical problems were neoplastic and gastrointestinal diseases and no significant differences between the 
groups were identified. Among cases of neoplasia, lymphoid malignancies were slightly more common in 
FIV-infected cats (16/75, 21.3%) than uninfected cats (30/230, 13%).  
 
Comparison of survival time between FIV-infected and uninfected deceased cats 
Thirty-eight FIV-infected and 134 uninfected cats died during the study period. Kaplan Meier survival 
curves are shown in Figure 1. There was no difference in survival age (p=0.8, log-rank test) or survival time 
(p=0.4, log-rank test) between FIV-infected cats and uninfected cats. 
 
 
Discussion 
 
In this study, we combined analysis of hematologic and biochemical changes, major clinical problem and 
outcome in client-owned cats tested for FIV. FIV-infected cats were compared with an uninfected control 
group adjusted for age and sex. The prevalence of FIV in this group of predominantly sick cats was 14.6%, 
which is in accordance with previous studies of sick cats from the Asia Pacific region where FIV prevalence 
data are consistently among the highest found internationally.21,22 In contrast, the finding of a single cat 
with FeLV antigenemia among 288 cats tested is consistent with the very low prevalence of FeLV in 
Australia.23 Analysis of risk factors for FIV infection identified that mixed breed, male cats were more likely 
to be infected than purebred, female cats. Age also was a risk factor with older cats (>5 years old) being 4 
times more likely to be FIV-infected than younger cats (≤5 years old). Similar risk factors have been 
reported worldwide demonstrating that our group displays characteristics typical for FIV-infected cat 
populations.2,4,6,17 
 
A substantial proportion of FIV-infected cats was anemic (38%), lymphopenic (50.9%) or hyperproteinemic 
(40%). However, similar trends were observed in FIV-uninfected cats where 49.4% were anemic, 49.4% 
lymphopenic and 48.7% hyperproteinemic. Multiple hematologic and biochemical abnormalities have 
been described as occurring commonly in FIV-infected cats, although matched, uninfected cats were not 
Major clinical problem FIV-infected  
(n=75) 
FIV /FeLV-uninfected 
 (n=230) 
p= 
Cardiorespiratory  5 6.7% 18 7.8% 1.0 
Endocrine  4 5.3% 15 6.5% 1.0 
Gastrointestinal 10 13.3% 36 15.6% 0.7 
Genitourinary  4 5.3% 9 3.9% 0.5 
Healthy  4 5.3% 15 6.5% 1.0 
Immune mediated  3 4.0% 12 5.2% 1.0 
Infectious 10 13.3% 24 10.4% 0.5 
Neoplasia (total) 
       lymphoid neoplasia 
24 
16 
32.0% 
21.3% 
55 
30 
23.8% 
13% 
0.2 
0.1 
Neurological  4 5.3% 20 8.6% 0.5 
No final diagnosis 7 9.3% 26 11.7% 0.8 
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included in these early studies.4,11,24-26 This highlights the importance of including a control sample when 
attempting to ascribe clinical relevance to such observations.  
 
Figure 1 Kaplan-Meier curves showing survival of FIV-infected and FIV-uninfected cats.  
Legend: Curves for FIV infected and uninfected groups indicate the proportion of surviving cats in each group at a 
given age (Figure A) or after a given time after testing (Figure B).  
 
Footnote: Variables also examined but not significant (p>0.25) were absolute erythrocyte reticulocyte, leukocyte, 
neutrophil (segmented and band), monocyte, eosinophil, basophil, lymphocyte and platelet counts, inorganic 
phosphate, glucose, creatinine, urea, total calcium, alanine aminotransferase, alkaline phosphatase, bilirubin, total 
protein, globulin, potassium, and chloride. 
 
 
Significant differences in serum sodium concentrations were observed between infected and non-infected 
cats. The majority of controls were hyponatremic. Hyponatremia is the most common electrolyte disorder 
in sick humans and results from  a diverse range of disease states and interventions.27 These include liver 
disease, renal disease, vomiting, diarrhea, congestive heart failure, diuretic treatment and hypotonic fluid 
administration.28 FIV-infected cats were as likely to be hyponatremic as hypernatremic but, interestingly, 
infected cats were much less likely than controls to be hyponatremic. As the investigation of factors 
affecting sodium balance in individual cats was beyond the scope of this study, we can only speculate as to 
why there may be a decreased risk of hyponatremia in FIV infection. One explanation is a tendency for 
hypernatremia in infected cats that offsets hyponatremia seen in uninfected, sick cats. Significantly 
increased plasma sodium concentrations were reported in FIV-infected cats from 43 months post-
experimental infection.29 Among field cases, hypernatremia was present in 6% of 48 FIV-infected cats.24 
Hypotonic fluid losses through vomiting, diarrhea, fever, renal compromise and decreased water intake 
can contribute to increased plasma sodium concentrations. Renal diseases are suspected in FIV infection, 
but a causal association has been difficult to prove.30 We found no difference between FIV-infected cats 
and controls in plasma creatinine concentration, and genitourinary diseases were not a major problem in 
either group. Thirst could be decreased in FIV infection by a central effect, because some FIV isolates are 
neurotropic, or secondary to cognitive dysfunction, similar to AIDS dementia.31,32 
 
An increased risk of hyperglobulinemia was reported in 2 controlled studies of natural FIV infection.13,15 
This likely reflects polyclonal B cell expansion which is a hallmark of HIV infection in humans and has been 
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documented in both natural and experimental FIV infection.33,34  In experimentally-infected cats followed 
longitudinally, plasma globulin concentration increased up to, but not after, 4.5 years post-infection.29 It 
was postulated that this observation was due to the eventual onset of B cell loss. Advanced FIV infection is 
characterized by profound lymphoid depletion.10,35,36 In a cross-sectional study of natural infection, Walker 
et al found lower proportions of B lymphocytes in cats with advanced disease compared with those at 
earlier stages.37 In our study, hyperglobulinemia was seen in 21.6% of FIV-infected cats and in a similar 
proportion (23.3%) of uninfected cats. The mean age at diagnosis of FIV-infected cats was 9.8 years and it 
is possible that many had been infected for years, which might explain why no association with increased 
plasma globulin concentration was identified. Thomas and others reported a similar finding.15 They 
demonstrated significant lymphopenia and hypergammaglobulinemia in cats naturally infected with FIV 
compared with controls, but when this relationship was analyzed in relation to age, it was found that 
neither variable was associated with FIV in cats > 8 years of age.  
 
FIV infection carried an increased risk of monocytopenia. Walker and Canfield also reported significant 
monocytopenia in FIV-infected pet cats compared with clinically matched, uninfected cats.37 Bone marrow 
examinations of cats in this study identified a normal or proliferating myeloid pool. In cats with terminal 
illness, FIV sequences were found predominantly in cells of the monocyte/macrophage lineage raising the 
possibility of a direct viral effect on monocyte maturation as a cause of monocytopenia.38  
 
Direct comparison between controlled field studies is hampered by differences in study populations, data 
collection and analyses. Notwithstanding these differences in study populations and design, when data 
from controlled field studies, including ours, are considered  as a whole no hematologic deficits have been 
consistently associated with FIV infection.13-16,18,39 Thus, although retrovirus testing is indicated in the 
investigation of hematologic abnormalities, their presence in a sick, FIV-infected cat should not be 
interpreted as evidence that the prognosis for that cat is worse, compared with an uninfected cat with 
similar hematologic findings. For example, a number of abnormalities have been described in FIV-infected 
cats that could contribute to anemia, including decreased or aberrant erythroid maturation and 
hemostatic abnormalities.18,25 40 However, anemia is a complex, multifactorial problem and its cause or 
causes may not always be identified in a sick cat with multiple problems. The fact that no other cause has 
been identified in an anemic patient infected with FIV does not imply that the problem is necessarily a 
consequence of FIV infection. 
 
In 1 in 5 FIV-infected cats, the major clinical problem was lymphoid malignancy. Several lines of evidence 
support that, just as in HIV infection, there is a group of lymphoproliferative malignancies associated with 
FIV infection. An increased risk of developing lymphoma in natural FIV infection has been demonstrated.41 
Histopathological and immunohistochemical studies describe high-grade, B cell, extranodal neoplasms, 
features characteristic of HIV-associated lymphomas.42 It will be important to further characterize 
malignancies arising in FIV-infected cats in the field to understand the spectrum of relationships between 
FIV and neoplasia and their etiologies. 
The survival time was comparable between FIV-infected and uninfected cats. This contradicts a still widely 
held belief that FIV infection confers decreased life expectancy, but is in agreement with recent case 
control studies investigating similar numbers of FIV-infected pet cats as described in our study.6,17 
Similarly, survival in cats experimentally infected with FIV over a 6.5 year period (10/10) was comparable 
with that in uninfected controls (9/10).29 In the largest study of almost 10,000 retrovirus tested pet cats, 
including 1100 seropositive for FIV, the survival rate at 6 years was 65% compared to 90% for uninfected 
cats.43 Interestingly, if deaths during the first 100 days were excluded, survival of FIV-infected cats was 
94% and 80% at 3 and 6 years, respectively, compared with controls. There is evidence that euthanasia 
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based on the diagnosis of FIV infection may contribute to an observation of decreased survival in studies of 
FIV-infected cats. Firstly, an investigation of risk factors for mortality in United Kingdom cat adoption 
centers found that, although FIV was the major single reason for euthanasia, no natural deaths could be 
attributed to this infection.44 Secondly, Ravi and others reported that, of 58 FIV seropositive cats studied, 
17 were euthanized at testing and in 9 of those the reason was the positive test result itself, rather than a 
specific clinical problem.17  
 
The in-house testing kits used here perform well with sensitivities and specificities for FIV antibody 
detection approaching 100% when compared with western blot or with each other.21,45 Confirmatory 
western blot testing was not performed but, as the results would be expected to vary little from serology, 
its value is questionable. The definitions of FIV-infected and FIV-uninfected used here combine history 
with results of serologic and, where indicated, molecular testing. This approach is necessary because of 
seroconversion following vaccination. Although it introduces potential errors in determining infection 
status, any such errors could have affected only a small proportion of cases reported here. The prevalence 
of FIV may have been higher than the 14.6% reported. Five cats that tested seropositive for FIV but with 
uncertain vaccination status, tested negative on PCR and were considered to be FIV-uninfected. This 
assumption may be false. It is not possible to eliminate the potential for vaccine-induced rather than 
infection-associated antibody in all cases. The sensitivity of PCR methodologies for detecting FIV is 
expected to be less than that of serology. The reported estimate of sensitivity of the PCR tests used here is 
similar, although lower, than estimates for serology.19 Virus isolation after cocultivation of peripheral 
blood mononuclear cells is not practical to use as a confirmatory test because it is not commercially 
available and is not applicable to retrospective data sets. On the other hand, exclusion of another 5 
seropositive cats of uncertain infection status may have falsely decreased the prevalence. A requirement 
for supportive evidence for defining FeLV antigen positive cats was imposed here because of the low 
prevalence of FeLV in this area and the subsequent poor positive predictive value of in-house tests.23 
 
There are limitations to our study. The control population comprising cats ‘at-risk’ for FIV infection was 
selected because of its clinical relevance. These controls were crucial in identifiying the similarity of clinical 
abnormalities detected in cats tested for FIV, regardless of the outcome of the test. This control group is 
unlikely to be representative of the total population of FIV-uninfected cats. The quality of data from 
retrospective studies is limited by non-standardized collection and incomplete data sets. The recording of 
the major clinical problem carries an element of subjectivity and does not account for the presence of 
multiple problems. The clinical consequences of FIV infection may be subtle and inconsistently detected at 
a population level, an issue that has hindered demonstration of pathogenicity of FIV strains infecting non-
domestic species.46 Many FIV-infected cats were censored from the survival analysis because they were 
still alive at the time of completion of the study and this should be noted when interpreting the data. 
Despite these drawbacks, studies of natural infection provide information relevant for practitioners faced 
with sick, FIV-infected cats.   
 
Initial reports implying that FIV infection by itself imparts a poor prognosis should be interpreted with 
caution. Until surrogate markers for FIV disease progression are validated in longitudinal studies of 
naturally-infected cats, the prognosis for an individual FIV-infected cat should be determined without 
regard to its FIV status. 
 
 
Footnotes 
a FIV, FeLV Rapid Immunomigration, AGEN Biomedical Ltd, Acacia Ridge, Queensland, Australia 
b Snap Combo, IDEXX Laboratories, Zetland, New South Wales, Australia 
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c Gribbles Veterinary Pathology, Clayton, Victoria, Australia 
d Vetpath Laboratory Services, Ascot, Western Australia 
e Fel-O-Vax ® FIV, Boehringer Ingelheim, Germany 
f Microsoft Excel RAND function, 2007 
g SAS statistical software, release 9.3, 2002–10, SAS Institute Inc., Cary, NC, USA 
h http://sydney.edu.au/vetscience/biostat/macros/multi_about.shtml 
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